↓ Skip to main content

Making SENSE - Sustained Effort Network for treatment of Status Epilepticus as a multicenter prospective registry

Overview of attention for article published in BMC Neurology, November 2015
Altmetric Badge

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
44 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Making SENSE - Sustained Effort Network for treatment of Status Epilepticus as a multicenter prospective registry
Published in
BMC Neurology, November 2015
DOI 10.1186/s12883-015-0486-y
Pubmed ID
Authors

Christoph Kellinghaus, Nicolas Lang, Andrea O. Rossetti, Stephan Rüegg, Christian Tilz, Eugen Trinka, Iris Unterberger, Zeljko Uzelac, Felix Rosenow

Abstract

Evidence regarding the different treatment options of status epilepticus (SE) in adults is scarce. Large randomized trials cover only one treatment at early stage and suggest the superiority of benzodiazepines over placebo, of intravenous lorazepam over intravenous diazepam or over intravenous phenytoin alone, and of intramuscular midazolam over intravenous lorazepam. However, many patients will not be treated successfully with the first treatment step. A large randomized trial covering the treatment of established status (ESETT) has just been funded recently by the NIH and will not start before 2015, with expected results in 2018; a trial on the treatment of refractory status with general anesthetics was terminated early due to insufficient recruitment. Therefore, a prospective multicenter observational registry was set up; this may help in clinical decision-making until results from randomized trials are available. SENSE is a prospective, multicenter registry for patients treated for SE. The primary objective is to document patient characteristics, treatment modalities and in-house outcome of consecutive adults admitted for SE treatment in each of the participating centres and to identify predictors of outcome. Pre-treatment, treatment-related and outcome variables are documented systematically. To allow for meaningful multivariate analysis in the patient subgroups with refractory SE, a cohort size of 1000 patients is targeted. The results of the study will provide information about risks and benefits of specific treatment steps in different patient groups with SE at different points of time. Thus, it will support clinical decision-making and, furthermore, it will be helpful in the planning of treatment trials. DRKS00000725.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 5%
Japan 1 2%
Ethiopia 1 2%
Unknown 40 91%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 25%
Student > Ph. D. Student 5 11%
Student > Bachelor 4 9%
Professor > Associate Professor 4 9%
Student > Master 4 9%
Other 10 23%
Unknown 6 14%
Readers by discipline Count As %
Medicine and Dentistry 21 48%
Neuroscience 5 11%
Psychology 4 9%
Agricultural and Biological Sciences 3 7%
Biochemistry, Genetics and Molecular Biology 2 5%
Other 3 7%
Unknown 6 14%